MALVERN, Pa., June 06, 2025 - TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, announced the approval of a new inducement grant for Jim Hagen, the company's Senior Vice President of Strategic Commercial Operations. Effective June 2, 2025, Hagen will receive an option to purchase 75,000 shares of TELA Bio's common stock, along with restricted stock units covering 30,000 shares. The stock options are priced at $1.42 per share, the closing price on the grant date, with a ten-year term. They will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following 36 months. The restricted stock units will also vest in equal annual installments over four years. These awards are contingent upon Hagen's continued service with TELA Bio.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。